Celgene Corp. (NASDAQ:CELG)

Net product sales demonstrated a consistent and aggressive upward trajectory between 2014 and 2018, increasing from US$ 7,564 million to US$ 15,265 million. This growth represents a total increase of approximately 102% over the five-year period, driven primarily by the strong performance of a few core pharmaceutical products.

Primary Growth Drivers

REVLIMID® served as the dominant revenue contributor throughout the period, showing steady annual growth from US$ 4,980 million in 2014 to US$ 9,685 million in 2018. Similarly, POMALYST®/IMNOVID® experienced significant expansion, tripling its annual revenue from US$ 680 million to US$ 2,040 million. OTEZLA® exhibited the most rapid relative growth, ascending from US$ 70 million in 2014 to US$ 1,608 million by 2018.

Stable and Emerging Revenue Streams

ABRAXANE® maintained a stable growth pattern, increasing moderately from US$ 848 million to US$ 1,062 million. VIDAZA® and ISTODAX® remained relatively stagnant, with VIDAZA® fluctuating slightly around the US$ 600 million mark and ISTODAX® remaining consistent between US$ 63 million and US$ 79 million. IDHIFA® represents a new entry into the portfolio, with initial revenues recorded in 2017 at US$ 20 million, growing to US$ 72 million by 2018.

Declining Product Lines

A downward trend is observed in the performance of legacy products. THALOMID® saw a consistent year-over-year decline, falling from US$ 221 million in 2014 to US$ 114 million in 2018. Azacitidine for injection also experienced a significant contraction, with revenues dropping from US$ 78 million to US$ 23 million over the same period.

The overall revenue profile indicates a high level of concentration, as the growth in net product sales is heavily weighted toward REVLIMID®, POMALYST®/IMNOVID®, and OTEZLA®. The decline in several older product lines was more than offset by the accelerated scaling of these primary assets.